A PYMNTS Company

US: FTC focuses on Bristol-Celgene deal review

By  |  March 26, 2019
US: FTC focuses on Bristol-Celgene deal review

According to a report from Reuters, the US Federal Trade Commission (FTC) has sought additional information from Bristol-Myers Squibb and Celgene and is focusing on the companies’ psoriasis treatments as part of its review of their planned merger, Bristol-Myers announced on Tuesday, March 26.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “The parties understand that the FTC’s review is focused on marketed and pipeline products for the treatment of psoriasis,” Bristol-Myers stated in a filing.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Celgene’s psoriasis drug Otezla brought US$448 million in sales in the quarter ended December 31. Bristol-Myers is also developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.